Eli Lilly (LLY) said Tuesday that it has launched 7.5 milligram and 10 milligram single-dose vials of Zepbound or Tirzepatide, priced at $499 per month through its self-pay Journey program.
The company also said it has lowered the prices of its 2.5 milligram and 5 milligram vials to $349 and $499 per month, respectively.
These new options are only available through "LillyDirect," Eli Lilly said, a system for direct pricing that removes third-party supply chain involvement.
Zepbound is also available in prefilled pens, with weekly maintenance doses of 5 milligrams, 10 milligrams, or 15 milligrams, the company said.
The company's shares were up 1.8% in recent Tuesday premarket activity.
Price: 896.51, Change: +15.11, Percent Change: +1.7
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.